Conference Coverage

Three days of beta-lactam beat clinically stable CAP


 

REPORTING FROM ECCMID 2018

The primary endpoint was clinical cure at day 15: no fever, absence of or improvement in respiratory symptoms (dyspnea, cough, purulent sputum, and cackles), and no need for additional antibiotic treatment for any indication.

Secondary endpoints were cure at day 30, 30-day mortality, adverse events, length of stay, return to usual activities by day 30, and quality of life at day 30.

Many of the generally elderly patient cohort had comorbid illnesses, including diabetes (about 20%), chronic obstructive pulmonary disease (about 35%), and coronary insufficiency (about 14%). About 20% were active smokers. Less than 10% had gotten a pneumococcal vaccine in the past 5 years.

At admission, more than half of patients were dyspneic, 80% had cough, and 39% had purulent sputum. The median PSI/PORT Score was 82.

Pages

Recommended Reading

Risks identified for drug-resistant bacteremia in cirrhosis
MDedge Internal Medicine
Common food additive makes C. difficile more virulent
MDedge Internal Medicine
Drug combo indicated for bacterial pneumonia
MDedge Internal Medicine
Reported penicillin allergies hike inpatient costs
MDedge Internal Medicine
FDA warns against clarithromycin use in patients with heart disease
MDedge Internal Medicine
Unusual antibiotic resistance found in more than 200 bacteria
MDedge Internal Medicine
MDedge Daily News: Antibiotic resistance leads to ‘nightmare’ bacteria
MDedge Internal Medicine
FDA advisory committee votes to recommend first once-daily aminoglycoside antibiotic
MDedge Internal Medicine
Don’t shorten therapy for older, sicker cellulitis patients
MDedge Internal Medicine
ESBL-resistant bacteria spread in hospital despite strict contact precautions
MDedge Internal Medicine